Aditxt, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Aditxt’s performance over the past year. My goal is to translate complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Aditxt is a biotech company based in Mountain View, California, focused on two main areas:

• Immune System "Retraining" (ADI™): Instead of just suppressing the immune system, their ADI™ platform aims to "re-train" it. This could help the body accept transplanted organs or stop attacking its own tissues. It is designed as a simple skin injection rather than a complex hospital procedure.
• Early Disease Detection (Pearsanta): Their subsidiary, Pearsanta, develops blood tests to catch diseases like cancer and endometriosis early. They use "Mitomic®" technology, which looks for damage in mitochondrial DNA to spot health issues before they become serious.

2. Major wins and progress

The company is currently in the research phase, meaning they are building their technology rather than selling finished products.

• ADI-100 Progress: They finished successful lab and animal testing. They are now working with the Mayo Clinic to prepare for human trials for Stiff Person Syndrome, aiming to enroll patients in 2026.
• Diagnostic Expansion: Pearsanta is developing a "Prostate Test" (MPT™) and an "Endometriosis Test" (MET™). These aim to provide simpler, more accurate ways to diagnose conditions that currently require years of testing or invasive procedures.
• Refining the Business: In September 2025, Aditxt and Pearsanta ended their licensing agreement for "AditxtScore" technology. This simplifies their structure, allowing Pearsanta to focus on its own diagnostic pipeline.
• Strategic Acquisitions: In 2024, Aditxt agreed to acquire Evofem Biosciences, a women’s health company, for roughly $100 million in stock and debt. This move aims to diversify their business beyond pure research.

3. Financial health (The "Burn" Rate)

Aditxt is not yet profitable. They are in an "investment phase," spending heavily on research, labs, and regulatory filings.

• Revenue Profile: For the year ending December 31, 2023, the company reported about $0.2 million in revenue from legacy services, while spending over $30 million on operations.
• Cash Position: Recent filings show the company held less than $1 million in cash.
• Cash Needs: Developing drugs is expensive. Because they lack steady income, they rely on raising money from investors. In 2024, they sold more shares and issued debt. For you, this means the company frequently issues more shares, which reduces your ownership percentage. They have also used reverse stock splits to keep their share price high enough to stay listed on the Nasdaq.

4. Key risks

• Regulatory Hurdles: Even with good lab results, regulators may not approve their trials or tests. Their diagnostic tests require rigorous validation to gain official clearance.
• The "All-or-Nothing" Nature: Success depends entirely on their technology passing clinical trials. If the science fails, the company has little else to fall back on.
• Unproven Commercial Success: Their technology is still largely unproven. They must compete in a tough market and prove their tests are better than current options.
• Going Concern Risk: Because they have little cash and high expenses, their auditors have expressed doubt about the company’s ability to stay in business without securing more funding.

Final Thought for Investors: Aditxt is a high-risk, speculative play. Because they are currently burning through cash to fund research and have very little revenue, their survival depends on their ability to raise more capital and successfully move their treatments through clinical trials. If you are considering an investment, keep a close eye on their cash balance in future filings and any updates regarding their progress with the Mayo Clinic and the FDA.